Lilly rides Mounjaro, Zepbound to better
Time:2024-05-21 22:19:01 Source:opinionsViews(143)
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Previous:Defending champion South Carolina to open season in Las Vegas against Michigan
Next:College baseball notebook: Conference tournaments to decide NCAA automatic bids and many at
You may also like
- Fresh heartache for cancer
- Former aide and consultant close to U.S. Rep. Cuellar plead guilty and agree to aid investigation
- Baby Reindeer's Jessica Gunning reenacts stalker Martha's pose as she joins co
- From Jabba the Hutt and Teletubby Hill to Drinking Dinosaur and the Wedding Cake
- Mohammad Mokhber: Who is Iran’s acting president?
- Inside Instagram 'bully' Katherine Asplundh's extravagant wedding to billionaire husband
- US utility pledges more transparency after lack of notice it empowered CEO to make plant decisions
- Kohli propels Bengaluru to 60
- France is trying Syrian ex